


**AMENDED CLAIMS**

1-10. (Canceled)

11. (Currently amended) A parenteral pharmaceutical composition with injection site toleration comprising a therapeutically effective amount of an Active Pharmaceutical Ingredient; a compound of Formula (Ia),



or a pharmaceutically acceptable salt thereof, a  $\beta$ -cyclodextrin, a pharmaceutically acceptable preservative, a pharmaceutically acceptable vehicle, and an optional pharmaceutically acceptable excipient, wherein the preservative demonstrates pharmaceutically acceptable antimicrobial preservative effectiveness.

12. (Canceled)

13. (Currently amended) The pharmaceutical composition according to Claim [[12]] 11 wherein the  $\beta$ -cyclodextrin is 2-hydroxypropyl- $\beta$ -cyclodextrin or sulfobutyl ether- $\beta$ -cyclodextrin.

14. (Currently amended) The pharmaceutical composition according to claim 11 wherein the preservative is selected from thimerosal, propylene glycol, phenol, or meta-cresol ~~or a combination thereof~~.
15. (Currently amended) The pharmaceutical composition according to claim 14 wherein the preservative is about 2.5 to about 3.5 mg/mL of meta-cresol, the cyclodextrin is sulfobutyl ether- $\beta$ -cyclodextrin, and wherein the pharmaceutically acceptable salt is the citrate monohydrate salt.
16. (Currently amended) The pharmaceutical composition according to claim 14 wherein the preservative has a binding value to the cyclodextrin that is less than  $[[a]]$  the binding value of the Active Pharmaceutical Ingredient compound of Formula (1a) to cyclodextrin.
- 17-18. (Canceled)
19. (Currently amended) The pharmaceutical composition according to claim 16 wherein the binding value of the ~~Active Pharmaceutical Ingredient compound of Formula (1a)~~ to cyclodextrin is between  $800\text{ M}^{-1}$  and  $31,000\text{ }3,000\text{ M}^{-1}$ .
- 20-28. (Canceled)
28. 29. (New) A pharmaceutical composition comprising about 10 mg/mL of a compound of Formula (1a), about 3.3 mg/mL meta-cresol, about 63 mg/mL sulfobutyl ether- $\beta$ -cyclodextrin, and a pharmaceutically acceptable vehicle.
29. 30. (New) A method for the treatment of emesis in an animal comprising administering to said animal a composition according to Claim 11.